Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide first identified for its role in regulating sleep architecture. Unlike conventional sedative-hypnotics, DSIP promotes restorative slow-wave sleep while preserving normal sleep cycles and minimizing residual daytime drowsiness.

Beyond sleep regulation, DSIP has demonstrated clinical utility in addiction medicine, notably in managing opioid and alcohol withdrawal, with success rates reported as high as 97% in opioid withdrawal and 87% in alcohol withdrawal. Additional studies suggest roles in pain relief, stress modulation, and neuroprotection.

Despite its promise, the FDA currently classifies DSIP as a Category 2 high-risk bulk substance, and it is not approved for therapeutic use in the United States.